IHH Healthcare Stock

Equities

IHH

MYL5225OO007

Healthcare Facilities & Services

End-of-day quote BURSA MALAYSIA 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
6.27 MYR +0.32% Intraday chart for IHH Healthcare +2.45% +3.98%

Financials

Sales 2024 * 22.06B 4.63B 6.31B Sales 2025 * 23.58B 4.95B 6.75B Capitalization 55.22B 11.59B 15.8B
Net income 2024 * 1.73B 363M 495M Net income 2025 * 1.92B 402M 549M EV / Sales 2024 * 2.81 x
Net Debt 2024 * 6.85B 1.44B 1.96B Net Debt 2025 * 6.5B 1.36B 1.86B EV / Sales 2025 * 2.62 x
P/E ratio 2024 *
31.5 x
P/E ratio 2025 *
28.8 x
Employees 65,000
Yield 2024 *
1.27%
Yield 2025 *
1.37%
Free-Float 24.07%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.32%
1 week+2.45%
Current month+3.64%
1 month+3.64%
3 months+3.12%
6 months+5.20%
Current year+3.98%
More quotes
1 week
6.12
Extreme 6.12
6.34
1 month
6.00
Extreme 6
6.34
Current year
5.93
Extreme 5.93
6.34
1 year
5.64
Extreme 5.64
6.34
3 years
5.12
Extreme 5.12
7.34
5 years
4.55
Extreme 4.55
7.34
10 years
3.85
Extreme 3.85
7.34
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 23-09-30
Investor Relations Contact - -
Corporate Officer/Principal 58 21-04-30
Members of the board TitleAgeSince
Director/Board Member 67 12-01-23
Chairman 67 11-03-29
Director/Board Member 64 20-12-31
More insiders
Date Price Change Volume
24-04-26 6.27 +0.32% 6,941,200
24-04-25 6.25 +0.81% 3,912,900
24-04-24 6.2 -0.64% 5,765,900
24-04-23 6.24 +1.46% 9,538,400
24-04-22 6.15 +0.49% 6,007,000

End-of-day quote BURSA MALAYSIA, April 25, 2024

More quotes
IHH Healthcare Berhad is a Malaysia-based integrated healthcare provider. The Company's segments include Hospital and Healthcare, IMU Health, Labs, PLife REIT and Others. It operates its Hospital and Healthcare segment in Singapore, Malaysia, India, Greater China, Turkey and Europe and Southeast Asia. The IMU Health segment is engaged in providing educational services. The Labs segment provides diagnostic laboratory services. The PLife REIT segment is a real estate investment trust. Through its portfolio of brands, such as Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway, the Company offers its patients comprehensive and personalized care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging, and rehabilitation. It provides day-to-day healthcare services through outpatient treatment, routine check-ups, and vaccinations. Its secondary care comprises specialist consultation, local surgeries, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
6.27 MYR
Average target price
7.13 MYR
Spread / Average Target
+13.72%
Consensus